...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors.
【24h】

Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors.

机译:海洋生物碱亮光胺B作为激酶抑制剂的新衍生物的合成和初步生物学评估。

获取原文
获取原文并翻译 | 示例
           

摘要

New derivatives of the marine alkaloid leucettamine B were prepared in five steps with overall yields ranging from 23 to 30%. The key step of our strategy has been the sulfuritrogen displacement under solvent-free microwave irradiation of (5Z) 5-benzo[1,3]-dioxo-5-ylmethylene-2-ethylsulfanyl-3,5-dihydroimidazol-4-one 3 with a mono-protected ethylenediamine 2. After deprotection of the N-Boc group, the amino derivative of leucettamine B 5 was subjected to reductive amination in two steps with retention of configuration of the double bond, to lead to eight new analogs of leucettamine B. The effect of these compounds on CK1alpha/beta, CDK5/p25, and GSK-3alpha/beta were investigated.
机译:通过五个步骤制备了海洋生物碱亮白胺醇B的新衍生物,总产率为23%至30%。我们策略的关键步骤是(5Z)5-苯并[1,3]-二氧代-5-基亚甲基-2-乙基硫基-3,5-二氢咪唑-4-的无溶剂微波辐射下的硫/氮置换一个带有单保护的乙二胺2的3。在将N-Boc基团脱保护后,将亮氨酸B 5的氨基衍生物分两步进行还原胺化,并保留双键的构型,从而生成8个新的类似物。研究了这些化合物对CK1alpha / beta,CDK5 / p25和GSK-3alpha / beta的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号